A mechanistic evaluation of the Syrian hamster embryo cell transformation assay (pH 6.7) and molecular events leading to senescence bypass in SHE cells by Pickles, JC et al.
A
t
s
J
A
a
b
c
a
A
R
R
A
A
K
C
M
S
S
p
1
t
c
g
m
f
r
H
I
E
B
h
1Mutation Research 802 (2016) 50–58
Contents lists available at ScienceDirect
Mutation Research/Genetic  Toxicology  and
Environmental Mutagenesis
jo ur nal homep ag e: www.elsev ier .com/ locate /gentox
Comm u ni t y add ress : www.elsev ier .com/ locate /mutres
 mechanistic  evaluation  of  the  Syrian  hamster  embryo  cell
ransformation  assay  (pH  6.7)  and  molecular  events  leading  to
enescence  bypass  in  SHE  cells
essica  C.  Picklesa,∗,1, Kamala  Pantb,  Lisa  A.  Mcgintya,2, Hemad  Yasaeia,3, Terry  Robertsa,
ndrew  D.  Scottc,  Robert  F.  Newbolda
Institute of Cancer Genetics and Pharmacogenomics, Brunel University London, Kingston Lane, Uxbridge, Middlesex UB8 3PH, United Kingdom
BioReliance Corporation, 14920 Broschart Road, Rockville, MD 20850-3349, USA
Unilever, Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedford MK44 1LQ, United Kingdom
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 9 February 2016
eceived in revised form 1 April 2016
ccepted 1 April 2016
vailable online 9 April 2016
eywords:
ell transformation assay
orphological transformation
enescence bypass
a  b  s  t  r  a  c  t
The  implementation  of  the  Syrian  hamster  embryo  cell  transformation  assay  (SHE  CTA)  into  test  batter-
ies  and  its  relevance  in  predicting  carcinogenicity  has been  long  debated.  Despite  prevalidation  studies
to ensure  reproducibility  and  minimise  the subjective  nature  of  the  assay’s  endpoint,  an underlying
mechanistic  and  molecular  basis  supporting  morphological  transformation  (MT)  as an  indicator  of car-
cinogenesis  is still  missing.  We  found  that  only  20%  of  benzo(a)pyrene-induced  MT  clones  immortalised
suggesting  that,  alone,  the  MT phenotype  is insufﬁcient  for senescence  bypass.  From  a  total  of  12 B(a)P-
immortalised  MT lines,  inactivating  p53  mutations  were  identiﬁed  in  30%  of  clones,  and  the  majority  of
these  were  consistent  with  the potent  carcinogen’s  mode  of action.  Expression  of p16  was  commonly
silenced  or markedly  reduced  with extensive  promoter  methylation  observed  in  45%  of  MT clones,  whileyrian hamster
16/CDKN2A
Bmi1  was  strongly  upregulated  in  25%  of  clones.  In instances  where  secondary  events  to  MT  appeared
necessary  for  senescence  bypass,  as evidenced  by a transient  cellular  crisis,  clonal  growth  correlated  with
monoallelic  deletion  of the  CDKN2A/B  locus.  The  ﬁndings  further  implicate  the importance  of  p16  and  p53
pathways  in  regulating  senescence  while  providing  a molecular  evaluation  of  SHE  CTA  −derived  variant
MT  clones  induced  by  benzo(a)pyrene.
© 2016  The  Authors.  Published  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license. Introduction
Reliable assessment of carcinogenic risk is essential for the pro-
ection of human health and reducing the incidence of human
ancer. Historically, rodent bioassays have been considered the
old standard for toxicological studies, but increasing legislative
easures have encouraged the reduction of the numbers of ani-
Abbreviations: SH, syrian hamster; SHE, syrian hamster embryo; CTA, cell trans-
ormation assay.
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mals used for chemical and agrochemical testing, while placing a
complete ban on animal testing in the cosmetics industry [1–3].
Although a variety of in-vitro assays are available for incorpora-
tion into test batteries, including those with mutagenicity and
chromosomal aberration (clastogenicity) endpoints, cell transfor-
mation assays have been considered promising additions given
their potential to be able to detect both genotoxic and non-
genotoxic carcinogens [4,5] whilst showing good correlation with
rodent bioassay data.
The process of cell transformation is believed to recapitulate
stages of carcinogenesis, since fully transformed cells have been
shown to possess anchorage-independent growth and to form
tumours at sites of injection when explanted into athymic mice
[6,7]. Molecular studies characterising the process of initial events
leading to morphological transformation (MT) are limited [8] and
have been largely based on the analysis of mass cultured SHE cells
treated with agents known to induce transformation [9,10], even
though the SHE-MT assay itself is clonogenic. Despite recent efforts
by ECVAM to validate the SHE CTA in terms of assay reproducibility
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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nd protocol standardisation while providing photo-catalogues to
ocument colony characteristics [11–13], the incorporation of the
HE CTA into test batteries has been hindered by concerns over
he assay’s subjective nature and lack of available mechanistic data
upporting morphological transformation (MT) as a suitable pre-
ictor of carcinogenesis.
The Syrian hamster embryo cell transformation assay (SHE CTA)
as distinct advantages over other CTAs in that it employs a het-
rogeneous cell population of normal diploid embryo-derived cells
hich are capable of metabolically activating carcinogens. This con-
rasts with the Balb/c and Bhas cells used in other CTAs, which are
erived from p53-deﬁcient strains and, in the latter case, express an
ctivated H-ras oncogene. Additionally, Syrian hamster cells have
 rate of spontaneous immortalisation much more akin to that of
uman cells, that is to say substantially lower than immortaliza-
ion frequencies observed in mouse cells [14]. Cellular senescence
s an essential barrier against uncontrolled proliferation and must
e bypassed during malignant transformation to permit clonal evo-
ution and tumour progression [15,16]. Human cells reach the end
f their proliferative potential due to telomere erosion (known
s replicative senescence) which signals a DNA damage response.
enescence can also be induced prematurely, either by oncogene
ctivation (OIS) or as premature stress-induced senescence (SIPS)
ue to inadequate culture conditions, and in vivo following changes
o surrounding microenvironments [17]. In small rodents, tel-
merase is constitutively switched on meaning that premature
enescence can be studied in isolation from events leading to
elomere-dependent replicative senescence [18].
The primary objective of the present study was to evaluate fur-
her the SHE CTA in order to determine the validity of the MT
henotype in predicting events leading to senescence bypass, and
o characterise key somatic genetic and epigenetic events leading
o the immortalisation of MT-derived SHE cells, in order to con-
rm the molecular relevance of the assay to the process of cancer
evelopment in vivo.
. Materials and methods
.1. Cell culture
Syrian hamster embryo-derived (SHE) cells were grown at
7 ◦C ± 1 ◦C with 10% CO2 ± 1% in Dulbecco’s modiﬁed Eagle’s
edium LeBoeuf’s modiﬁcation without L-Glutamine (DMEM-L,
H 6.7) (Quality Biological, USA) supplemented with 20% (v/v)
etal calf serum, 1% GlutaMAXTM and 100 units/mL penicillin and
00 g/mL streptomycin (Invitrogen, Life Technologies, USA). Cells
ere considered terminally senescent when no signs of cell growth
ere visible for over a month since seeding and without further
ub-culture.
.2. The Syrian hamster cell transformation assay (pH 6.7)
On day 1 primary SHE cells were plated in equilibrated condi-
ioned medium [19] to obtain between 25 to 45 colonies per dish
s described by others elsewhere [20]. After 24 h, cells were treated
ith a ﬁnal concentration of 5 g/l  benzo(a)pyrene prepared in
 maximum of 0.2% (v/v) DMSO. The ﬁnal concentration of B(a)P
orresponded to that used in positive controls for predictive SHE
ssays. After a 7 day incubation period cell plates were ﬁxed in
ethanol and stained in 10% (v/v) Giemsa. Each colony was visu-
lly assessed for features of morphological transformation (MT) and
cored [12,21].earch 802 (2016) 50–58 51
2.3. Obtaining SHE CTA colony-derived cells
The SHE CTA was performed in parallel at BioReliance (KP) and at
Brunel University (JCP). Unstained colonies from treated [B(a)P] and
vehicle control (DMSO) plates with clear-cut morphologies (nor-
mal  or MT)  were labelled before returning to the incubator. One
plate at a time, the medium was  removed and the cells washed
in CMF-HBSS (Invitrogen Gibco®) before lifting off around half of
each colony of interest with a blunted Pasteur pipette. Disaggre-
gated clones were transferred into 0.5 mL  DMEM-L conditioned
medium (diluted 1:1 with fresh complete DMEM-L) in a 24-well
plate to establish colony-derived SHE CTA cultures. The remaining
colonies were ﬁxed and stained in Giemsa. At BioReliance, whole
colonies were picked using cloning cylinders (KP). From this point
onwards clones were expanded until senescence or reaching over
100 PD to conﬁrm immortality.
2.4. Gene expression by qRT-PCR
Nucleic acids were extracted and cDNA prepared as previously
described [22]. The reference genes GAPDH and beta-actin were
selected from a panel of reference genes (Primerdesign Ltd.) and
expression values compared to a panel of six early passage, DMSO-
treated SHE cells derived from normal SHE CTA colonies. Primer
sequences for qRT-PCR are listed in the supplementary data.
2.5. Copy number variation
Separate FAM labelled assays were designed speciﬁcally for
p16 (NCBI ref. AH010240.2) exon 1, ARF (AF443796.1) exon 1
and exon 2, p15 (NM 001281539.1) and p53 (NM 001281661.1).
VIC-labelled SDHA (DQ402977.1) was used as the reference gene
and duplexed with each gene of interest. 25 g gDNA was ampli-
ﬁed using PrecisionPLUS 2X qPCR Mastermix (Primerdesign Ltd)
in a ﬁnal total volume of 20 l per reaction each performed in
quadruplet and repeated three times. Data was analysed using Copy
Caller Software v2.0 (Life Technologies). All primers for CNV were
designed and validated by PrimerDesign Ltd. and remain their intel-
lectual property.
2.6. Mutation screening
Coding sequences of the tumour suppressor genes p16 and p53
were Sanger sequenced using overlapping primers designed to
span exon 1 and 2 of p16 and exons 2–9 of p53, as described
previously [22] and following gel-excision and puriﬁcation.
2.7. DNA methylation analysis
Colony-derived SHE cultures were analysed for patterns of
methylation at the p16 promoter region. gDNA was  bisulphite con-
verted prior to methylation analysis. A 457 bp region containing the
SH p16 promoter was then ampliﬁed by PCR using Phusion U poly-
merase (Thermo Scientiﬁc) and gel-excised before insertion into
pJET1.2/blunt linearised cloning vector (Thermo Scientiﬁc). DNA
was extracted from a minimum of 10 bacterial cultures containing
the correctly ligated plasmid and bisulphite sequenced to estimate
the extent of methylation present at each CpG site. Four MT  colony-
derived cell lines (BP MT2, BP MT6, BP MT7  and BP MT8) were
treated with the demethylating agent 5′-Aza-2′-deoxycytidine and
monitored over a period of 4 weeks. Two doses of 5 M 5-aza-dC
(Sigma) were added to fresh culture media at 4 h intervals before
removal.
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.8. Senescence-associated beta-galactosidase staining
The SA- gal stain was freshly prepared at pH 6 according to
ebacq-Chainiaux et al. [23] in ultra-pure water. Plates were stored
t RT in the dark. Fixed and stained cells were imaged and counted
or intense blue staining corresponding to SA- gal activity.
. Results
.1. Morphological transformation does not guarantee
enescence bypass
Normal SHE colonies (Fig. 1A) were well organised, stained
ight purple in the dibasic Giemsa stain and their cell growth
as arranged in a ﬂowing monolayer of contact-inhibited cells,
onsistent with available photocatalogues [12]. Morphological
ransformation (MT) was associated with highly disorganised pat-
erns of cell growth along with nuclear aggregation and cell
tacking (Fig. 1A). MT  cells were typically more elongated with
ncreased nuclear to cytoplasmic ratios and stained dark purple or
lue in Giemsa due to their basophilic nature.
To understand the relationship between MT  and senescence
ypass leading to immortalisation, SHE cells were picked from
nstained SHE CTA colonies (supplementary data) and kept in cul-
ure to determine their lifespan (Fig. 1B). Irrespective of treatment
nd laboratory performing the CTA, all normal colony-derived cells
eased to proliferate before 35 population doublings (Fig. 1B and
) and entered senescence as judged by increased SA- gal stain-
ng, general cell enlargement and ﬂattening (data not shown). Cells
ere maintained in this senescent state with no signs of cell divi-
ion for up to two months. Cells derived from MT  colonies also
ig. 1. MT  characteristics alone are insufﬁcient for cellular immortalisation.
he SHE CTA was  performed at two laboratories under equivalent conditions with benz
HE  colonies after 7 days growth and stained in Giemsa. (B) Resulting normal and morph
ifespan and frequency of immortalisation. (C) Growth curves of picked colonies; the maj
mmortalised either continued to proliferate exponentially and retained MT characteris
e.g.  BP MT4) noted by increased doubling times and visibly enlarged, senescent-like cell
oincided with the appearance of pockets of clonal growth that continued to expand (F).earch 802 (2016) 50–58
mostly entered terminal senescence by 35 PD (Fig. 1B and C),
indicating that scoring of MT  alone is insufﬁcient to guarantee
senescence bypass. We  observed an immortalisation frequency of
20% and 8% for BP MT  colonies picked at the BioReliance and Brunel
laboratories respectively (Fig. 1B).
3.2. Secondary event(s) to MT characteristics permit
immortalisation
A total of 10 B(a)P – treated MT  colony-derived cultures acquired
immortality and continued to proliferate beyond 100 PD from the
single cell stage; 4 clones originating from BioReliance and 6 from
Brunel. Half of the immortalised BP MT  colonies were found to be
immortal from the outset and continued to exponentially expand
with 22–33 h population doubling times (Fig. 1C). The remaining BP
MT  colony-derived cultures that went on to immortalise, entered a
cellular crisis characterised by increased population doubling times
of up to 80 h, that lasted around 20 days (Fig. 1C). During this tem-
porary phase SHE cells became senescence-like in terms of cell
morphology (Fig. 1E) before the emergence of rare pockets of clonal
growth (Fig. 1F) which continued to proliferate indeﬁnitely. A sin-
gle rare DMSO-treated MT  scored colony gave rise to a population
of cells with indeﬁnite growth potential, also emerging after a pro-
longed period of cellular crisis, suggesting a spontaneous frequency
of immortalisation equal to 0–5% MT  colonies.
We conclude that the MT  phenotype and endpoint of the SHEpredispose SHE cells to acquiring cellular immortality follow-
ing secondary rare and necessary events for senescence bypass.
Such events are clearly observable following colony picking and
establishment at around 20 PD due to the drastic changes in cell
o(a)pyrene and DMSO. (A) Examples of normal and morphologically transformed
ologically transformed colonies were picked and grown out to determine cellular
ority of established colonies senescenced by 35 PD. BP MT colony populations that
tics (D) e.g. BP MT2, or entered a cell crisis following 10–20 population doublings
s (E). Following a lag period of up to 3 weeks, secondary events subsequent to MT
J.C. Pickles et al. / Mutation Research 802 (2016) 50–58 53
Table  1
p53 point mutations confer growth advantages and are identiﬁed in B(a)P-induced clones but no p16 mutants were identiﬁed.
p16 Codon change Translated mutation Human equivalent Hotspot Location
All c345CT > TC CAC/TGC > CAT/CGC 115–116aa HIS/CYS > HIS/ARG 116aa HIS/ARG 0 Exon 2
p53  Codon change Translated mutation Human equivalent Hotspota Location
All c561 GA > AG GAG/AGC > GAA/GGC 187–188aa GLU/SER > GLU/GLY 185aa ASP/SER 18 (0) DBD
BP  MT9  c482 G > T CGT > CTT 161aa ARG > LEU 158aa ARG 264 (102) DBD
BP  MT10 c808C > T CGG > TGG 270aa ARG > TRP 267aa ARG 65 (34) DBD
BP  MT11 c734 G > C TGC > TCC 245aa CYS > SER 242aa CYS 198 (20) DBD
BP  MT12 c752 G > T CGG > CTG 251aa ARG > LEU 248aa ARG 1544 (121) DBD
Colony-derived SHE CTA cells were screened for p53 and p16 mutations within gene coding regions. (A) No p16 point mutations were identiﬁed, (B) four non-synonymous
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S53  mutants were identiﬁed in established B(a)P-treated, MT colony-derived SHE li
umber  of known human tumours with the same amino-acid mutation according t
a Number of human p53 mutations found at that codon according to the Universa
orphology as the majority of the cell population enters senes-
ence. In contrast, in instances where no crisis period was  observed,
HE BP MT  clones appeared immortal from the outset although
econdary events to MT  may  have still taken place early on during
olony formation and thus not observable in terms of cell morphol-
gy and division rates.
.3. P53 mutations present in 30% of immortal SHE MT
olony-derived clones
Our previous studies using Syrian hamster dermal cells (SHD)
ndicated that senescence bypass induced by benzo(a)pyrene could
e achieved by a co-operative two-step mechanism involving
53 transversion mutations and p16 transcriptional gene silenc-
ng [22]. Colony-derived SHE cells were screened for mutations in
he coding regions of the key tumour suppressor genes p53 and
16 (AF292567). No mutations were identiﬁed in p16 sequences,
lthough c345CT > TC was common to all cultures and controls
ested and matches the newly sequenced genomic information
p53 Mdm2 Rb1 Bmi-1 p16 ARF p15
1.25 0.18 1.43 2.77 0.004 0.008 0.041
0.56 0.09 0.86 2.29 0.008 0.002 0.042 
1.61 0.12 0.67 5.44 0.007 0.011 0.043
P+3 0.66 1.56 0.82 4.91 3.28 1.36 3.32 
P+7 3.46 1.70 3.55 13 .32 0.59 0.75 3.73 
P+9 2.61 3.65 3.44 34 .95 0.49 0.67 2.64 
P+12 5.07 0.18 0.52 39 .80 0.63 0.52 0.12 
P+16 2.21 1.57 5.87 55 .96 0.61 0.43 1.65
P+26 1.05 0.94 4.82 21 .52 0.06 0.12 0.78 
P+3 2.79 0.02 0.27 0.70 0.10 0.56 0.04 
P+5 0.04 0.41 1.20 0.61 0.47 0.36 
P+10 1.32 0.14 2.41 1.33 0.13 0.26 0.09 
P+13 2.07 4.03 5.39 1.55 0.30 0.58 0.23 
P+17 2.16 13.33 7.67 2.32 0.92 0.47 1.16
P+20 0.28 1.77 2.50 0.21 0.38 0.10 
P+24 1.11 0.63 1.73 2.31 0.37 0.76 0.17 
P+2 0.55 0.86 1.81 2.70 2.62 3.12 1.44 
P+3 0.57 0.76 1.80 3.52 3.62 5.23 2.33 
P+13 1.32 0.03 0.24 0.78 0.51 1.28 0.84 
P+15 1.53 0.16 1.24 8.47 0.83 1.08 0.91 
P+17 1.53 0.10 1.48 8.72 0.94 0.84 0.65 
P+18 1.18 0.17 1.25 4.59 0.62 1.04 0.60 
P+2 1.06 0.50 2.80 3.76 0.76 0.56 0.68 
P+3 0.35 0.29 1.71 4.66 0.88 0.39 0.24 
P+4 0.67 0.47 1.87 7.93 2.61 0.82 1.95 
P+5 0.10 0.18 0.70 13 .24 2.30 0.27 0.09 
P+7 0.21 0.26 0.68 7.20 1.77 0.23 0.15 
P+9 0.99 0.13 0.81 4.18 0.48 0.44 0.15 BP  M
P+12 2.83 1.13 0.55 1.92 0.64 1.32 0.23 
P+14 0.95 0.02 0.15 0.29 0.45 0.65 0.08 BP  M
BP 
BP 
BP M
BP 
Gene  targe ts
SHE primary
BP MT1
BP MT2
BP MT3
BP MT4
ig. 2. Gene expression in SHE CTA derived B(a)P-induced clones.
Heat map’ summarising gene expression proﬁles for p16 and p53-pathway members in 
ifespan. Ct values were normalised to the reference genes GAPDH and beta-actin and com
HE  CTA. The double strikethrough line indicates the time point at which a crisis-phase w located within the DNA binding domain (DBD); numbers in brackets represent the
 p53 database [27].
ation database (UMD) [26].
for Mesocricetus auratus (WGS Project APMT01). Similarly, a com-
mon variant was also identiﬁed for p53 (c561 GA > AG), as shown
in Table 1. A further two  SHE CTA-derived B(a)P-treated MT  lines
(BP MT11 and BP MT12) were sourced from previous studies in
our laboratory [24] bringing the total BP MT-immortalised cultures
to twelve. p53 point mutations were identiﬁed in four separate
BP MT  lines; all were located within the protein’s DNA binding
domain corresponding to known human p53 mutational hotspots
(Table 1), predicted to negatively impact p53 protein function
[25] and largely consistent with transversion mutations typical
of B(a)P’s well-characterised mode of action. Thus 30% of immor-
talised B(a)P-treated lines MT  lines were found to have a mutated
p53 whilst no point mutations were identiﬁed in any normal (N)
colony-derived cells or in the spontaneous DMSO MT line. Analysisthe cultures were initially established, suggests a heterogeneous
cell population indicating that the presence of p53 point mutations
conferred a selective growth advantage.
p53 Mdm2 Rb1 Bmi-1 p16 ARF p15
P6 1.82 0.64 2.67 2.65 0.02 0.05 0.05
P8 1.88 0.15 0.74 2.14 0.09 0.25 0.11
P10 0.86 0.09 0.40 2.39 0.46 0.90 0.25
P12 1.69 0.18 1.55 3.45 0.50 1.01 0.24
P14 1.43 0.26 0.68 1.82 0.20 0.62 0.57
P16 1.47 0.06 0.33 3.09 0.22 0.40 0.12
P20 1.39 0.07 0.24 3.71 0.15 0.27 0.10
P21 1.17 0.08 0.41 3.73 0.20 0.25 0.11
P7 1.17 3.06 2.18 1.56 1.13 1.06 3.75
P8 0.65 4.99 2.94 2.31 3.70 1.92 13.45
P10 0.58 2.73 1.59 2.99 3.53 1.86 10.93
P12 1.47 1.44 0.82 7.62 1.72 0.61 2.90
P14 2.62 2.19 1.17 2.90 1.13 1.52 1.98
P16 2.53 0.68 0.14 0.47 0.68 1.17 1.54
P6 1.84 0.87 2.40 5.32 0.20 0.08 0.22
P7 1.56 1.36 2.94 3.46 0.15 0.06 0.32
P8 2.36 1.26 4.65 4.63 0.41 0.18 0.43
P9 1.64 2.30 2.88 2.15 0.18 0.10 0.19
P10 1.64 1.34 3.93 3.16 0.87 0.31 0.58
P12 1.36 2.02 0.93 0.54 0.35 0.70 0.06 12.00
10.00
P7 1.93 2.57 3.53 3.79 0.14 0.07 1.07 8.00
P8 1.79 1.34 2.21 4.41 0.21 0.09 1.23 6.00
P9 2.21 1.65 2.40 2.25 0.13 0.10 0.58 4.00
P10 2.72 2.62 3.89 1.29 0.12 0.14 0.65 2.00
P11 3.07 0.78 4.12 6.73 0.47 0.21 1.17 1.00
P13 2.39 2.63 1.83 0.54 0.12 0.35 0.50 0.80
P14 3.53 1.23 2.86 1.94 0.46 0.90 0.19 0.60
0.40
T11 1.76 1.22 2.06 3.19 0.77 0.4 0.5 0.20
0.10
T12 1.03 1.01 4.17 3.95 0.61 0.47 0.29 0.01
MT8
MT7
T 5
MT6
Gen e targets
immortalised B(a)P-induced SHE  CTA cell lines at successive passages during their
pared to DMSO-treated, early passage non-transformed colonies derived from the
as  observed across the cell population and senescence barriers were overcome.
5 on Res
3
c
B
t
b
a
p
o
t
e
s
s
t
a
i
A
a
s
c
g
w
3
c
T
e
a
i
l
b
u
i
a
P
3
b
b
T
S
S
l4 J.C. Pickles et al. / Mutati
.4. Reduced expression of CDKN2A/B genes in immortal SHE MT
olony-derived cells
Expression of senescence-associated genes was  analysed in
P MT  colony-derived cells as the cells bypassed senescence
o identify any common characteristics and potential predictive
iomarkers in MT  clones. Levels of p16 transcripts were gener-
lly reduced in immortalised B(a)P-induced clones and ARF and
15 were also expressed at low levels (Fig. 2). In contrast p16 was
verexpressed in senescent SHE cells derived from DMSO non-
ransformed colonies, while primary untreated SHE cells minimally
xpressed all three CDKN2A/B transcripts. An increase in the expres-
ion of p16 and p15 was associated with the observed increase in
enescent-like morphology and increase in population doubling
imes in clones BP MT1, BP MT3, BP MT4  and BP MT6  (Figs. 1 C
nd 2). Transcript levels of p16 and p15 were markedly decreased
n emerging immortal cells which went to on divide indeﬁnitely.
RF was also generally repressed but the differences in transcript
bundance appeared to be more subtle pre- and post-crisis. The
imultaneous change in transcript levels and cell morphology indi-
ates the importance of functional p16 and also p15 in promoting
rowth arrest and suggests inactivation of these senescence path-
ays during immortalisation.
.5. Over-expression of bmi1 mRNA in immortal SHE MT
olony-derived cells
Bmi-1 expression was quantiﬁed in our various SHE cell clones.
his analysis indicated a strong overexpression of Bmi1 transcripts,
specially in BP MT1  (Fig. 2). Given that Bmi1 has been shown to
ct oncogenically and has been implicated in inducing immortal-
sation [28], we hypothesised that its over-expression may  have
ed to p16 downregulation and contributed towards senescence
ypass in SHE clones. Further work is needed to conﬁrm this reg-
latory phenomenon in Syrian hamster cells. In human cells, Bmi1
s known to regulate p16 transcription both by direct binding to
n upstream gene element and indirectly at a chromatin level by
olycomb protein assembly [29,30].
.6. Single copy loss of CDKN2A/B genesIn an effort to explain further the mechanism of senescence
ypass in SHE CTA colony-derived MT  lines, separate copy num-
er variation assays were carried out for the three genes encoded
able 2
ummary of genetic changes in SHE CTA colony-derived cells.
Immortal Cell crisis p53 mutation p16-methylatio
SHE primary N
DMSO N N
DMSO MT1 Y Y
BP N N
BP MT1 Y Y Y 
BP  MT2 Y Y
BP MT3 Y Y 
BP  MT4 Y Y
BP MT5 Y Y
BP MT6 Y Y Y 
BP  MT7 Y Y
BP MT8 Y Y
BP MT9 Y p.R161L Y
BP  MT10 Y Y p.R270W Y
BP  MT11 Y n/aa p.C425S 
BPMT12 Y n/aa p.R251L 
HE CTA colony-derived cells were analysed for gene mutations in p16 and p53, DNA m
ocus  and p53.
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at the CDKN2A/B locus and for p53. All colony-derived cells retained
2 copies of p53, but single allelic loss was  observed within the
CDKN2A/B locus in 5 out of 12 immortal BP MT colony-derived cul-
tures (Table 2). Interestingly 3 out of 5 BP-induced immortalised
lines that overcame a cell crisis phase (with prolonged population
doubling times) were found to have lost a copy of the CDKN2A/B
locus. BP MT1  and BP MT6  had a single copy of the entire CDKN2A/B
locus encompassing p16, ARF and p15 but when analysed prior
to 35 population doublings both copies were present, suggest-
ing the deletion of one allele during the immortalisation process.
The remaining 2 lines were predicted to have two copies of the
CDKN2A/B locus, with increased doubling times associated with the
accumulation of its p53 mutation (discussed earlier). Similarly, the
entire CDKN2A locus was  found to be monoallelic in BP MT11 and
BP MT12 while BP MT3  lacked a copy of exon 2, which is common
to both ARF and p16, as well as exon 1 which is unique to ARF
(Table 2). Collectively, these ﬁndings further suggest that loss of
key tumour suppressor genes at the CDKN2A/B locus contributes
towards senescence bypass and, additionally, may  point towards
haploinsufﬁciency contributing to abrogation of senescence path-
ways.
3.7. DNA methylation of the SH p16 gene promoter in SHE MT
colony-derived immortal cells
Our recent studies using carcinogen-induced SH dermal cell
clones indicated that silencing of p16 gene expression was  asso-
ciated with promoter methylation [22]. In order to provide a more
comprehensive explanation for the reduced p16 transcript levels
in SHE CTA immortal colony-derived cultures, DNA methylation
levels were analysed in a 450 bp region upstream of the p16 start
site. Bisulphite sequencing showed that over 45% of all immortal
MT colony-derived SHE cells had methylated p16 promoters, with
methyl groups commonly located within the identiﬁed CpG islands
[31] (Fig. 3A). Patterns of promoter methylation were also observed
using methyl-speciﬁc PCR (data not shown). No methylation was
observed in any of the controls or in the spontaneous line DMSO
MT1.
To conﬁrm that p16 gene expression could be regulated by
promoter methylation, BP MT  lines were treated with the methyl-
transferase inhibitor 5-aza-2′ deoxycytidine (5-aza-dC). From 48 h
following the initiation of 5-aza-dC treatment, the proliferation
rates of the cells decreased (Fig. 3C), while the percentage of senes-
cent cells increased as shown by SA-gal staining and domination
n Gene copy number (CNV)
p16 exon1 p16/ARF exon2 ARF exon1 p15 p53
−/+ −/+ −/+
−/+ −/+
−/+ −/+ −/+ −/+
−/+ −/+ −/+ −/+
−/+ −/+ −/+ −/+
ethylation at the p16 promoter and copy number variations across the CDKN2A/B
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Fig. 3. The p16 promoter is methylated in 45% B(a)P-induced immortal MT clones.
Bisulphite sequencing was performed on the p16 promoter region of B(a)P-induced immortal MT colony-derived SHE cell lines. The extent of DNA methylation was analysed
at  32CpG sites; CpG site 1 is closest to the ATG start site and CpG site 32 is the most distant. A minimum of 10 colonies per sample were analysed. (A) 45% of analysed
MT  colonies were heavily methylated (black dots) and a further 25% of MT colonies were partially methylated at similar CpG sites. White (empty) symbols indicate no
methylation, black symbols represent >50% methylation, dark grey symbols 30–40% and light grey symbols 20% at each CpG site. When treated with 5-aza-dC methyl groups
were  removed following 4–8 days in BP MT2, BP MT7  and BP MT8 (supplementary) and corresponded to increases in p16 gene expression (B). (C) Treated cells were counted
every  2–3 days to calculate cumulative population doublings. (D) After 10 days of treatment plates were stained for SA- gal as an indicator of cellular senescence; (E) the
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eviation from the mean.
f the cultures with morphologically senescent cells (Fig. 3D and E).
fter 4–8 days, transcript levels of p16 signiﬁcantly increased com-
ared to untreated cells (Fig. 3B) and methyl groups were found to
ave been lost (Supplementary data). In the case of BP MT7, treat-
ent with the demethylating agent appeared to have permanent
ffects; the cells remained senescent and ceased to show signs of
roliferation (Fig. 3C). All other treated lines started to recover 2
eeks after the addition of 5-aza-dC, coupled with a return to low
16 expression levels. The data therefore provide persuasive evi-
ence that aberrant DNA methylation can also contribute towards
enescence-bypass of SHE CTA derived cultures.
. Discussion
The merits of incorporating the SHE CTA into test batteries for
afety and toxicological testing have long been debated. Although
ecent efforts by ECVAM to pre-validate the assay in terms of repro-
ucibility [13,21,32] and by the OECD to provide standardised assay
uidelines, are well advanced [33], a lack of molecular understand-
ng forging a mechanistic link between the assay’s end point and
arcinogenesis has hindered its widespread adoption as a suitable
nimal alternative [3]. Here, we have further evaluated the SHE CTA
y picking representative examples of MT  and non-transformed
olonies prior to staining in Giemsa and characterising molecu-
ar events leading to unlimited growth potential in cells derived
rom benzo(a)pyrene-induced morphologically transformed (MT)
lones.f 100 cells were counted per plate in triplicate, error bars represent the standard
We ﬁnd that MT  is insufﬁcient for senescence bypass. The
vast majority of MT  clones ceased to proliferate before they had
undergone 35 population doublings. Only 10–20% of B(a)P-treated
MT-derived clones continued towards immortality which was not
dissimilar to previous SHE growth studies where fewer than 30% of
MT colonies were estimated to immortalise [34]. Events secondary
to the MT  phenotype were often necessary for senescence bypass,
as indicated by the clear-cut crisis phase observed in around half
of the established SHE lines after 2–3 months following colony
picking. Rare events gave rise to rapidly dividing cells, which
curiously had lost their MT  phenotype, an observation that has
been noted previously by others. Additional events have histori-
cally been linked to cells acquiring the ability to grow in soft agar
(anchorage-independence) and to form tumours at the site of injec-
tion in athymic mice [34,35]. This is consistent with the notion that
immortalisation and senescence bypass, while rate-limiting, are
only the ﬁrst necessary steps towards progression to malignancy
[14,36,37].
Mutational analysis of p53 revealed that 30% of immortalised
B(a)P-induced MT  lines contained likely deleterious missense
mutations in the tumour suppressor gene DNA binding domain
[25,27]. The expected mutation frequency of B(a)P for a given hap-
loid gene (eg hprt) in Chinese hamster cells is 3 × 10−4/treated cell,
which is approximately thirty times greater than the spontaneous
rate of mutation [38]. Our observation that a relatively high pro-
portion of immortal SHE MT  clones contained a p53 mutation, can
be explained by the prolonged 7-day incubation of SHE cells ini-
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ially exposed to B(a)P during the SHE CTA. At the end of the assay
he average SHE colony contained 8 × 103 cells and was thus esti-
ated to undergo around 13 population doublings in the presence
f the carcinogen. Precisely how heterogeneous the embryo cells
re within a given colony and how this affects the population’s
rowth potential remains to be established. The data would suggest
hat those cells containing a p53 mutation were positively selected
uring successive subcultures as, post crisis, all transcripts analysed
ontained the mutated sequence.
Immortal MT  colony-derived cell lines that emerged from a
enescence-like phase without known point mutations in p53 pos-
essed only single copies of the genes encoded by the CDKN2A/B
ocus. Gene expression analysis associates the sudden decrease in
16 and p15 transcripts with copy number loss following the emer-
ence of rare clonal growth. Down-regulation of p16 and p15 mRNA
xpression at subsequent time points analysed remained stable,
eﬂecting the permanent allele loss. Deletions spanning 9p21 in
umans have been commonly associated with melanoma and mul-
iple other tumour types [39,40] while copy number loss in the
yrian hamster has previously been described in pancreatic and
ral tumours [41] and in our own laboratory has recently been
ssociated with carcinogen-induced senescence-bypass [22].
DNA methylation of several speciﬁc CpG sites located within
he ﬁrst 300 bp upstream of the p16 promoter was observed in
P MT-immortalised colony-derived cells. 40% of BP MT  clones
ere heavily methylated at CpG sites 40 bp upstream of the TSS,
hile presence of methylated CpG dinucleotides were observed in
nother 27% of clones at the same residues, suggesting a regulatory
ole. A putative TATA box was identiﬁed at −160 bp to the tran-
cription start site (data not shown) and three more commonly
ethylated CpG sites were identiﬁed upstream of this. Although
ost BP MT  colony-derived cells expressed p16 at low levels, lines
xpressing the lowest levels of p16 were identiﬁed to have the high-
st extent of DNA methylation at the p16 gene promoter. This is
onsistent with an inverse relationship in SH cells between the level
f p16 transcripts and presence of methyl groups [42,43], although
romoter methylation status alone was not sufﬁcient to predict
enescence bypass. Treatment with the methyltransferase inhibitor
-aza-dC led to a signiﬁcant increase in p16 expression after four
nd eight days exposure to the drug and this was  accompanied
ith the temporary loss of methyl groups at the p16 promoter, a
ecrease in cell division rates, and an increase in senescent cells
etected by SA-gal staining. The data suggests that DNA methyla-
ion at the promoter is important in suppressing p16 transcription
nd is likely to have a co-operative role in evading senescence bar-
iers since, overall, almost 70% of B(a)P-induced MT-derived lines
ere methylated.
Our previous studies using SH dermal ﬁbroblasts and a mass
ulture approach, have characterised carcinogen speciﬁc ﬁnger-
rints reﬂecting their mode of action, leading to senescence bypass
nd cellular immortalisation. A two-step model has been pro-
osed for B(a)P-induced SHD immortalisation: p53 inactivation
y point mutations (mainly G to T transversions) initially, fol-
owed by a ‘second hit’ targeting the p16-Rb pathway, either by
pigenetic silencing of p16 by DNA methylation, p16 single copy
oss, or p15 and Rb1 transcriptional down-regulation [22]. By com-
arison, in the present study, SHE immortal clones were overall
ound to have low levels of p16 and 70% of clones did not contain
16/ARF or p53 mutations. Extensive promoter methylation and/or
DKN2A/B locus single allele loss were correlated positively with
he reduced transcript levels identiﬁed. Additionally, we hypoth-
sise that overexpression of PRC1 polycomb protein Bmi-1 may
ave contributed towards p16 repression and evasion of senescence
arriers. Whether senescence in these instances was bypassed
olely via the p16/pRB pathway in isolation from p53 signalling
s unknown given that we were unable accurately to quantify lev-earch 802 (2016) 50–58
els of the p53 and p16 proteins via western blot (due to a lack of
available antibodies to SH). Although the p53 qPCR data suggests no
large change in gene expression, we cannot exclude that aberrant
post transcriptional modiﬁcations and/or signalling of downstream
effectors such as p21 are also likely to have played a role in evading
senescence barriers.
The molecular analysis of SHE CTA derived clones described
here provides additional evidence supporting the applicability of
the Syrian hamster as a suitable model for carcinogenesis stud-
ies. Along with our earlier studies using SHD cells [22 INK4B and
p53 tumour-suppressor genes drive induced senescence bypass in
normal diploid mammalian cells] it underscores its value in gain-
ing an understanding of senescence bypass mechanisms that drive
SIPS and OIS in isolation from the telomere-mediated replicative
senescence barriers that predominate in human cells [14,18]. In
the past the lack of sequence information for the Syrian ham-
ster has been experimentally restrictive for pursuing such studies
[3,22]. However, the Mesocricetus auratus genome has now been
shotgun sequenced and assembled into unannotated contigs (WGS
Project APMT01) and even more recently, its transcriptome has
been released [44] thanks to the use of SH in modelling Ebola [45].
Such ‘-omics’ advances will ultimately be beneﬁcial in the imple-
mentation of SH as a suitable model. As an example, our sequence
alignments of coding regions to WGS  sequences (see supplemen-
tary data) suggest that the CDKN2A/B locus is well conserved in SH,
of a similar size to that in humans (i.e. in excess of 35 KB) with
the same genomic organisation including the upstream regulatory
domain (RD) [41].
Efforts to improve and/or automate the scoring process of the
SHE CTA have had limited success. Such developments include
computerised image analysis to detect alterations in colony colour,
organisation and texture [46], and use of attenuated total reﬂection
Fourier-transform infrared (ATR-FTIR) microscopy to identify bio-
chemical signatures of MT  [47–49]. No unique predictive attribute
was visually identiﬁed from the remaining colony portions imaged
that in culture had unlimited growth potential. In our present study,
by picking and growing out morphologically transformed colonies
it was possible to uncover some of the key molecular events leading
to immortalisation of MT  clones.
We  appreciate that the data presented here is limited to
B(a)P-induced effects, a known potent mutagen and carcinogen
commonly used as one of the SHE CTA positive controls. We
recommend that the analysis now be extended to other known
carcinogens, including those inducing epigenetic or non-genotoxic
events, as proof of principle. Final concentrations of B(a)P used
in this study (5 g/ul) are estimated to be saturating in Syrian
hamster primary cells, as levels of DNA binding by its highly muta-
genic metabolised products [primarily 7,8-diol-9,10-epoxide-B(a)P
(BPDE)] level off at around a ﬁfth of this dose [50]. It may  there-
fore be worth considering how the observed molecular events may
change in relation to a decrease in chemical exposure. Given that
the morphologies of SHE MT  colonies differ slightly when per-
formed at pH 6.7 compared to pH 7.1–7.3 [21] we are currently
unable to comment on whether senescence bypass and subsequent
pathway aberrations take place at similar frequencies between all
versions of the SHE assay.
In conclusion, we provide an underlying mechanistic analysis
of the SHE CTA, as performed at pH 6.7. Ultimately, if combined
with suitable mechanistic and molecular data, the SHE assay could
provide a suitable in vitro predictor of carcinogenic potential to
be incorporated into regulatory testing strategies. In addition, the
implementation of (Q)SAR modelling alongside cell transformation
assays has been proposed to address false negatives and false posi-
tives in order to add further towards a weight of evidence approach
when assessing chemical data [51]. Of critical importance, the SHE
CTA has scope for both detecting and determining the mode of
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